CapsoVision (CV) closed FY 2025 with fourth quarter revenue of US$3.9 million, a basic EPS loss of US$0.16 per share, and trailing twelve month revenue of US$13.6 million alongside a trailing EPS loss of US$1.03 per share. Over recent quarters, revenue has moved from US$3.5 million in Q3 2025 and US$3.3 million in Q2 2025 to the latest US$3.9 million print. Basic EPS losses shifted from US$0.17 and US$2.02 over those same periods to US$0.16, leaving investors focused on how quickly margins can tighten and the path toward breakeven can firm up from here.

See our full analysis for CapsoVision.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely held narratives around CapsoVision's growth, risk, and margin potential.

15.3% Revenue Growth Versus Ongoing $25.3 Million Loss

• Over the last 12 months CapsoVision generated US$13.6 million in revenue while recording a trailing net loss of US$25.3 million, so revenue growth of 15.3% year on year is still paired with sizeable losses.
• Consensus narrative highlights strong forecasted revenue and earnings growth, yet that view sits against trailing losses where net income of US$25.3 million is negative and basic EPS over the same period is a loss of US$1.03. This means the growth story is based on future expectations rather than current profitability.
  • Analysts expect revenue to grow at 46.4% per year and earnings at 62.17% per year, while the most recent trailing figures show losses across every quarter in FY 2025.
  • This gap between 15.3% actual revenue growth and much higher forecast numbers is exactly where you need to decide how much weight to put on analyst models versus the current loss making position.

Quarterly Losses Narrow While Bulls Look To Profit Shift

• In FY 2025, quarterly net income moved from a loss of US$5.4 million in Q1 and US$4.6 million in Q2 to losses of US$7.9 million in Q3 and US$7.4 million in Q4, alongside basic EPS losses that ranged from US$2.47 in Q1 to US$0.16 in Q4.
• Bulls argue that this earnings trend is the early stage of a turn toward profitability, yet the current run rate still reflects sizeable quarterly losses, so the bullish case leans heavily on what happens over the next few years rather than what is in the recent results.
  • In the bullish narrative, earnings are expected to reach US$9.0 million by about 2029 from a current trailing loss of US$25.3 million, which is a very large swing in profit expectations relative to the present loss profile.
  • To line up with that bullish path, margins would need to move from roughly a 172.4% loss today to an 11.7% margin in three years. The current negative net income figures give you a clear reference point for how much needs to change.

Bulls point to aggressive revenue and margin targets on top of these FY 2025 numbers, so if you want to see how that optimistic path is built out in detail, it is worth checking the full bullish thesis in 🐂 CapsoVision Bull Case.

Premium 27.6x P/S Against Volatile Share Price

• CapsoVision trades at a P/S of 27.6x compared with 2.8x for the wider US Medical Equipment industry and 6.2x for peers, while the share price of US$7.51 has also been more volatile than the broader US market over the last three months.
• Bears focus on this valuation gap and the volatility, arguing that a high P/S multiple on a loss making company leaves little room for disappointment if revenue or margin progress does not track the forecasts.
  • With trailing revenue of about US$13.6 million and a trailing net loss of US$25.3 million, the current 27.6x P/S suggests investors are paying a premium even though earnings remain negative.
  • The share price volatility noted over recent months means any shift in expectations around that 46.4% revenue growth forecast or the move to profitability could lead to sharper price moves than for more steady peers.

Skeptics often point to this 27.6x P/S and the recent volatility as reasons to stress test the cautious view in more detail, so it can help to read how the bearish thesis walks through those risks in 🐻 CapsoVision Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CapsoVision on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading all this, it is clear the story mixes concern and optimism, so move quickly to review the numbers yourself and weigh up the 2 key rewards and 1 important warning sign.

See What Else Is Out There

CapsoVision combines sizeable trailing net losses with a premium 27.6x P/S multiple, so investors are paying up even while profitability remains out of reach.

If that mix of ongoing losses and a rich sales multiple makes you uneasy, it makes sense to compare alternatives using the 60 high quality undervalued stocks to find ideas priced with more modest expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.